REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Oxygen Containing Hetero Ring > The Hetero Ring Is Six-membered > Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos Polycyclo Ring System Having The Hetero Ring As One Of The CyclosPolycyclo Ring System Having The Hetero Ring As One Of The Cyclos patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.12/14/06 - 20060281808 - Process to extract quassinoids A means for the extraction and crystallization of quassinoids such as quassin and neoquassin from natural sources containing these compounds, using compounds that are Generally Recognized As Safe by the U.S. Food and Drug Administration is provided. In particular, a means for extraction that does not require use of lead ... 12/14/06 - 20060281807 - Quassinoid compositions for the treatment of cancer and other proliferative diseases The invention provides quassinoid compounds that are useful in treating cancer. The invention further provides a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of killing a cancer cell, and a method of treating cancer in a mammal. ... 06/22/06 - 20060135598 - Anti-first-pass effect compounds Safe, effective first-pass inhibiting compounds and citrus-derived substances are provided. Formulations containing the compounds are also provided as are methods for inhibiting the first pass effect. ... 06/15/06 - 20060128793 - Analogs of 17-hydroxywortmannin as p13k inhibitors wherein R1, R2, R3, and R8 are defined herein. ... 06/15/06 - 20060128792 - Deguelin as a chemopreventive agent for lung cancer The present invention provides the chemopreventive agent deguelin, a natural product isolated from Mundulea serica (Leguminosae), and derivatives thereof, for use in combination with a second agent for inhibiting growth premalignant and malignant lung cancer cells by causing G2/M arrest and apoptosis. Thus, the present invention provides deguelin-based combination therapies ... 06/08/06 - 20060122260 - Intermediates for aromatic polyketides as selective anticancer and antiviral agents The present invention relates to the finding of potentiality of aromatic polyketide intermediates in drug development and, in specific, use of these compounds in development of antiviral or anticancer medicines. ... 05/25/06 - 20060111433 - Use of angelicin and of its structural analogues for the treatment of thalassemia The use of angelicin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia is described. A structural analogue which is particularly preferred for this purpose is bergapten. ... 04/20/06 - 20060084698 - Methods for preparation and use of psorospermin analogs Psorospermin is a cytotoxic dihydrofuranoxanthone that has found to exhibit significant activity against various tumor cell lines. Unfortunately, psorospermin is no longer readily available from its natural plant source. The present invention is directed to a method for preparing psorospermin and psorospermin analogs. Methods are also disclosed for utilizing psorospermin ... 04/20/06 - 20060084697 - Pi3k antagonists as radiosensitizers A method for increasing radiosensitivity of a target tissue in a subject via administration of a PI3K antagonist to a target tissue in a subject. Also provided are methods for suppressing tumor growth and for inhibiting tumor blood vessel growth via administration of a PI3K antagonist. ... 04/13/06 - 20060079573 - Methods and compositions for preventing vasospasm Methods and compositions for preventing or reducing vascular smooth muscle contraction are provided. Exemplary compositions comprise an MLCK inhibitor, for example wortmannin, in an amount effective to prevent or reduce vascular smooth muscle vasospams by about 90% for at least about 20 minutes. Methods for identifying other modulators of MLCK ... 03/09/06 - 20060052438 - Bioactive compounds and methods of uses thereof as further defined herein. In additional aspects, the present invention provides compositions and kits comprising the compounds of the invention and methods for their use, for example, for the prevention or treatment of a cancer. ... 01/05/06 - 20060004087 - Tetracyclic compounds as estrogen ligands wherein R1, R2, R3, R4, Q, n, R8, R9, R10, and R11 have been defined in the specification; or a pharmaceutically acceptable salt thereof. The invention further provides methods for the preparation and use of the compounds. ... 12/08/05 - 20050272808 - Compositions and methods for the treatment of hypertension The present invention relates to use of 1,7-dioxaspiro[5.5]undecane and derivatives thereof for the preparation of a medicament for the treatment or prevention of hypertension. The invention also provides a method for treatment or prevention of hypertension using a medicament comprising 1,7-dioxaspiro[5.5]undecane or a derivative thereof as an active ingredient, such ... 11/24/05 - 20050261363 - Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same Disclosed herein are an acetone-extracted product obtained from gamboge resin and compounds further purified from said acetone-extracted product, including a new compound called formoxanthone A. The acetone-extracted product and the further purified compounds have been demonstrated to have activities in inhibiting the growth of tumor/cancer cells. Also disclosed are the ... 08/04/05 - 20050171191 - Anti-first-pass effect compounds Safe, effective first-pass inhibiting compounds and citrus-derived substances are provided. Formulations containing the compounds are also provided as are methods for their preparation and for inhibiting the first pass effect. ... 06/02/05 - 20050119334 - Novel compounds as semaphorin inhibitors wherein R1 and R3 are each independently hydrogen or a carboxyl group and R2 and R4 are each independently hydrogen or a hydroxyl group, or pharmaceutically acceptable salts thereof, which exhibit semaphorin-inhibitory activity and are useful as preventives or remedies for neuropathic and neurodegenerative diseases are provided. ... ### FreshPatents.com Support |